Autopsy report · NCT01687478

A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

“Interim assessment: Lack of efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 176 participants enrolled.
• Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Treatment Resistant Depression

Interventions

Olanzapine; Fluoxetine; Placebo

Participants

176

Sites

11

Countries

China

Trials that died the same way

• A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
  “Lack of efficacy determined at interim analysis” (80% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (78% match in meaning)
• Hydroxyurea in Primary Progressive Multiple Sclerosis
  “No efficacy (interim.analysis)” (72% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (71% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.